Home›Trial›NCT06132256

🔬NCT06132256Phase 2ACTIVE NOT RECRUITING

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Study Summary

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

Conditions

Idiopathic Pulmonary Fibrosis

Interventions / Drugs

Axatilimab Placebo

View on ClinicalTrials.gov ↗

Sponsor

Syndax Pharmaceuticals

Study Details

Enrollment145 participants

Primary Completion—

Lead SponsorSyndax Pharmaceuticals

Data Retrieved2026-04-11 04:27:50.896943+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.